---
layout: default
title: EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment
---

# EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment

**arXiv**: [2512.14019v1](https://arxiv.org/abs/2512.14019) | [PDF](https://arxiv.org/pdf/2512.14019.pdf)

**ä½œè€…**: Juseung Yun, Sunwoo Yu, Sumin Ha, Jonghyun Kim, Janghyeon Lee, Jongseong Jang, Soonyoung Lee

**åˆ†ç±»**: cs.LG, q-bio.QM

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºEXAONE Path 2.5ç—…ç†å­¦åŸºç¡€æ¨¡åž‹ï¼Œé€šè¿‡å¤šç»„å­¦å¯¹é½æ•´åˆç»„ç»‡å­¦ä¸Žåˆ†å­æ•°æ®ï¼Œä»¥æ›´å…¨é¢å»ºæ¨¡è‚¿ç˜¤ç”Ÿç‰©å­¦ã€‚**

ðŸŽ¯ **åŒ¹é…é¢†åŸŸ**: **å¼ºåŒ–å­¦ä¹ **

**å…³é”®è¯**: `ç—…ç†å­¦åŸºç¡€æ¨¡åž‹` `å¤šæ¨¡æ€å¯¹é½` `å¤šç»„å­¦æ•´åˆ` `å¯¹æ¯”å­¦ä¹ ` `å…¨åˆ‡ç‰‡å›¾åƒåˆ†æž` `ç²¾å‡†è‚¿ç˜¤å­¦` `ç”Ÿç‰©åŒ»å­¦äººå·¥æ™ºèƒ½` `Transformeræž¶æž„`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. çŽ°æœ‰æ–¹æ³•ä¸»è¦ä¾èµ–å•ä¸€ç»„ç»‡å­¦å›¾åƒï¼Œéš¾ä»¥æ•æ‰ç™Œç—‡è¿›å±•ä¸­è·¨åˆ†å­å±‚é¢çš„ç›¸äº’ä½œç”¨ï¼Œå¯¼è‡´å¯¹è‚¿ç˜¤ç”Ÿç‰©å­¦çš„ç†è§£ä¸å…¨é¢ã€‚
2. è®ºæ–‡æå‡ºEXAONE Path 2.5ï¼Œé€šè¿‡å¤šæ¨¡æ€å¯¹é½æ•´åˆç»„ç»‡å­¦ã€åŸºå› ç»„ã€è¡¨è§‚é—ä¼ å’Œè½¬å½•ç»„æ•°æ®ï¼Œå¹¶å¼•å…¥SigLIPæŸå¤±ã€F-RoPEæ¨¡å—å’Œé¢†åŸŸä¸“ç”¨æ¨¡åž‹æ¥å¢žå¼ºè¡¨å¾èƒ½åŠ›ã€‚
3. åœ¨Patho-BenchåŸºå‡†ä¸Šè¾¾åˆ°ä¸Žæœ€å…ˆè¿›æ¨¡åž‹ç›¸å½“çš„æ€§èƒ½ï¼Œåœ¨å†…éƒ¨ä¸´åºŠæ•°æ®ä¸­è¡¨çŽ°å‡ºæœ€é«˜é€‚åº”æ€§ï¼ŒéªŒè¯äº†å¤šç»„å­¦æ•´åˆçš„æœ‰æ•ˆæ€§å’Œé«˜æ•ˆæ€§ã€‚

## ðŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç™Œç—‡è¿›å±•æºäºŽå¤šä¸ªç”Ÿç‰©å±‚é¢çš„ç›¸äº’ä½œç”¨ï¼Œå°¤å…¶æ˜¯è¶…è¶Šå½¢æ€å­¦å¹¶æ¶‰åŠåˆ†å­å±‚é¢ï¼Œè¿™äº›å¯¹ä»…åŸºäºŽå›¾åƒçš„æ¨¡åž‹æ˜¯ä¸å¯è§çš„ã€‚ä¸ºäº†æ•æ‰æ›´å¹¿æ³›çš„ç”Ÿç‰©æ™¯è§‚ï¼Œæˆ‘ä»¬æå‡ºäº†EXAONE Path 2.5ï¼Œè¿™æ˜¯ä¸€ä¸ªç—…ç†å­¦åŸºç¡€æ¨¡åž‹ï¼Œå®ƒè”åˆå»ºæ¨¡ç»„ç»‡å­¦ã€åŸºå› ç»„å­¦ã€è¡¨è§‚é—ä¼ å­¦å’Œè½¬å½•ç»„å­¦æ¨¡æ€ï¼Œç”Ÿæˆä¸€ä¸ªæ›´å…¨é¢åæ˜ è‚¿ç˜¤ç”Ÿç‰©å­¦çš„æ•´åˆæ‚£è€…è¡¨å¾ã€‚æˆ‘ä»¬çš„æ–¹æ³•åŒ…å«ä¸‰ä¸ªå…³é”®ç»„ä»¶ï¼š(1) å¤šæ¨¡æ€SigLIPæŸå¤±ï¼Œå®žçŽ°è·¨å¼‚è´¨æ¨¡æ€çš„å…¨é…å¯¹å¯¹æ¯”å­¦ä¹ ï¼›(2) ç‰‡æ®µæ„ŸçŸ¥æ—‹è½¬ä½ç½®ç¼–ç (F-RoPE)æ¨¡å—ï¼Œä¿ç•™å…¨åˆ‡ç‰‡å›¾åƒä¸­çš„ç©ºé—´ç»“æž„å’Œç»„ç»‡ç‰‡æ®µæ‹“æ‰‘ï¼›(3) é’ˆå¯¹å…¨åˆ‡ç‰‡å›¾åƒå’ŒRNA-seqçš„é¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡åž‹ï¼Œä¸ºç¨³å¥çš„å¤šæ¨¡æ€å¯¹é½æä¾›åŸºäºŽç”Ÿç‰©å­¦çš„åµŒå…¥ã€‚æˆ‘ä»¬åœ¨ä¸¤ä¸ªäº’è¡¥åŸºå‡†ä¸Šè¯„ä¼°EXAONE Path 2.5ä¸Žå…­ä¸ªé¢†å…ˆçš„ç—…ç†å­¦åŸºç¡€æ¨¡åž‹ï¼šä¸€ä¸ªå†…éƒ¨çœŸå®žä¸–ç•Œä¸´åºŠæ•°æ®é›†å’Œè¦†ç›–80ä¸ªä»»åŠ¡çš„Patho-BenchåŸºå‡†ã€‚æˆ‘ä»¬çš„æ¡†æž¶å±•ç¤ºäº†é«˜æ•°æ®å’Œå‚æ•°æ•ˆçŽ‡ï¼Œåœ¨Patho-Benchä¸Šè¾¾åˆ°ä¸Žæœ€å…ˆè¿›åŸºç¡€æ¨¡åž‹ç›¸å½“çš„æ€§èƒ½ï¼ŒåŒæ—¶åœ¨å†…éƒ¨ä¸´åºŠè®¾ç½®ä¸­è¡¨çŽ°å‡ºæœ€é«˜çš„é€‚åº”æ€§ã€‚è¿™äº›ç»“æžœçªæ˜¾äº†åŸºäºŽç”Ÿç‰©å­¦çš„å¤šæ¨¡æ€è®¾è®¡çš„ä»·å€¼ï¼Œå¹¶å¼ºè°ƒäº†æ•´åˆåŸºå› åž‹åˆ°è¡¨åž‹å»ºæ¨¡å¯¹ä¸‹ä¸€ä»£ç²¾å‡†è‚¿ç˜¤å­¦çš„æ½œåŠ›ã€‚

## ðŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šç™Œç—‡è¿›å±•æ¶‰åŠç»„ç»‡å­¦ä¸Žåˆ†å­å±‚é¢çš„å¤æ‚ç›¸äº’ä½œç”¨ï¼ŒçŽ°æœ‰ç—…ç†å­¦åŸºç¡€æ¨¡åž‹ä¸»è¦åŸºäºŽå•ä¸€å›¾åƒæ¨¡æ€ï¼Œæ— æ³•å…¨é¢å»ºæ¨¡è‚¿ç˜¤ç”Ÿç‰©å­¦ï¼Œå¯¼è‡´å¯¹æ‚£è€…è¡¨å¾çš„å±€é™æ€§ã€‚çŽ°æœ‰æ–¹æ³•çš„ç—›ç‚¹åœ¨äºŽç¼ºä¹è·¨æ¨¡æ€å¯¹é½èƒ½åŠ›ï¼Œéš¾ä»¥æ•´åˆå¼‚è´¨æ•°æ®å¦‚åŸºå› ç»„å’Œè½¬å½•ç»„ä¿¡æ¯ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡çš„æ ¸å¿ƒè§£å†³æ€è·¯æ˜¯æž„å»ºä¸€ä¸ªå¤šæ¨¡æ€ç—…ç†å­¦åŸºç¡€æ¨¡åž‹ï¼Œé€šè¿‡è”åˆå»ºæ¨¡ç»„ç»‡å­¦ã€åŸºå› ç»„ã€è¡¨è§‚é—ä¼ å’Œè½¬å½•ç»„æ•°æ®ï¼Œç”Ÿæˆæ•´åˆçš„æ‚£è€…è¡¨å¾ã€‚è®¾è®¡ä¸Šï¼Œé‡‡ç”¨å¯¹æ¯”å­¦ä¹ å¯¹é½ä¸åŒæ¨¡æ€ï¼Œå¹¶å¼•å…¥ä¸“é—¨æ¨¡å—å¤„ç†ç©ºé—´ç»“æž„å’Œç”Ÿç‰©å­¦åµŒå…¥ï¼Œä»¥æ›´å…¨é¢åœ°åæ˜ è‚¿ç˜¤ç”Ÿç‰©å­¦ã€‚

**æŠ€æœ¯æ¡†æž¶**ï¼šæ•´ä½“æž¶æž„åŒ…æ‹¬æ•°æ®é¢„å¤„ç†ã€å¤šæ¨¡æ€å¯¹é½å’Œè¯„ä¼°é˜¶æ®µã€‚ä¸»è¦æ¨¡å—æœ‰ï¼šå¤šæ¨¡æ€SigLIPæŸå¤±ç”¨äºŽå…¨é…å¯¹å¯¹æ¯”å­¦ä¹ ï¼ŒF-RoPEæ¨¡å—ä¿ç•™å…¨åˆ‡ç‰‡å›¾åƒçš„ç©ºé—´æ‹“æ‰‘ï¼Œä»¥åŠé¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡åž‹ä¸ºå…¨åˆ‡ç‰‡å›¾åƒå’ŒRNA-seqæä¾›ç”Ÿç‰©å­¦åµŒå…¥ã€‚æµç¨‹ä¸Šï¼Œå…ˆé€šè¿‡å†…éƒ¨æ¨¡åž‹æå–å„æ¨¡æ€åµŒå…¥ï¼Œå†ä½¿ç”¨SigLIPæŸå¤±è¿›è¡Œå¯¹é½ï¼Œæœ€ç»ˆç”Ÿæˆæ•´åˆè¡¨å¾ç”¨äºŽä¸‹æ¸¸ä»»åŠ¡ã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„æŠ€æœ¯åˆ›æ–°ç‚¹æ˜¯å¤šæ¨¡æ€SigLIPæŸå¤±ã€F-RoPEæ¨¡å—å’Œé¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡åž‹çš„ç»“åˆã€‚ä¸ŽçŽ°æœ‰æ–¹æ³•çš„æœ¬è´¨åŒºåˆ«åœ¨äºŽï¼Œå®ƒä¸ä»…æ•´åˆå¤šç»„å­¦æ•°æ®ï¼Œè¿˜é€šè¿‡ä¸“é—¨è®¾è®¡å¤„ç†æ¨¡æ€å¼‚è´¨æ€§å’Œç©ºé—´ç»“æž„ï¼Œå®žçŽ°æ›´ç¨³å¥çš„å¯¹é½å’Œæ›´å…¨é¢çš„ç”Ÿç‰©å­¦å»ºæ¨¡ã€‚

**å…³é”®è®¾è®¡**ï¼šå…³é”®å‚æ•°è®¾ç½®åŒ…æ‹¬å¯¹æ¯”å­¦ä¹ ä¸­çš„æ¸©åº¦å‚æ•°å’ŒåµŒå…¥ç»´åº¦ï¼›æŸå¤±å‡½æ•°ä½¿ç”¨SigLIPæŸå¤±ï¼Œæ”¯æŒè·¨æ¨¡æ€å…¨é…å¯¹å¯¹æ¯”ï¼›ç½‘ç»œç»“æž„æ¶‰åŠTransformer-basedç¼–ç å™¨ç”¨äºŽæ¨¡æ€åµŒå…¥ï¼ŒF-RoPEæ¨¡å—é›†æˆæ—‹è½¬ä½ç½®ç¼–ç ä»¥å¤„ç†ç»„ç»‡ç‰‡æ®µï¼›æŠ€æœ¯ç»†èŠ‚è¿˜åŒ…æ‹¬ä½¿ç”¨é¢„è®­ç»ƒçš„é¢†åŸŸä¸“ç”¨æ¨¡åž‹åˆå§‹åŒ–ï¼Œä»¥å¢žå¼ºç”Ÿç‰©å­¦åŸºç¡€ã€‚

## ðŸ“Š å®žéªŒäº®ç‚¹

åœ¨Patho-BenchåŸºå‡†ä¸Šï¼ŒEXAONE Path 2.5ä¸Žå…­ä¸ªé¢†å…ˆæ¨¡åž‹ç›¸æ¯”ï¼Œè¾¾åˆ°æœ€å…ˆè¿›æ€§èƒ½ï¼ˆå…·ä½“æ•°æ®æœªçŸ¥ï¼Œä½†æè¿°ä¸ºâ€œon-parâ€ï¼‰ï¼Œè¦†ç›–80ä¸ªä»»åŠ¡ã€‚åœ¨å†…éƒ¨çœŸå®žä¸–ç•Œä¸´åºŠæ•°æ®é›†ä¸­ï¼Œå®ƒè¡¨çŽ°å‡ºæœ€é«˜çš„é€‚åº”æ€§ï¼ŒéªŒè¯äº†å¤šæ¨¡æ€è®¾è®¡çš„ä¼˜åŠ¿ã€‚æ¡†æž¶è¿˜å±•ç¤ºäº†é«˜æ•°æ®å’Œå‚æ•°æ•ˆçŽ‡ï¼Œæå‡äº†æ¨¡åž‹åœ¨å¤æ‚ä¸´åºŠçŽ¯å¢ƒä¸­çš„å®žç”¨æ€§ã€‚

## ðŸŽ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶åœ¨ç²¾å‡†è‚¿ç˜¤å­¦é¢†åŸŸå…·æœ‰é‡è¦åº”ç”¨ä»·å€¼ï¼Œå¯ç”¨äºŽç™Œç—‡è¯Šæ–­ã€é¢„åŽé¢„æµ‹å’Œæ²»ç–—å“åº”åˆ†æžã€‚é€šè¿‡æ•´åˆå¤šç»„å­¦æ•°æ®ï¼Œå®ƒèƒ½æä¾›æ›´å…¨é¢çš„æ‚£è€…è¡¨å¾ï¼Œè¾…åŠ©ä¸´åºŠå†³ç­–å’Œä¸ªæ€§åŒ–åŒ»ç–—ã€‚æœªæ¥å¯èƒ½æŽ¨åŠ¨ä¸‹ä¸€ä»£ç—…ç†å­¦å·¥å…·çš„å‘å±•ï¼Œä¿ƒè¿›è·¨æ¨¡æ€ç”Ÿç‰©åŒ»å­¦ç ”ç©¶ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Cancer progression arises from interactions across multiple biological layers, especially beyond morphological and across molecular layers that remain invisible to image-only models. To capture this broader biological landscape, we present EXAONE Path 2.5, a pathology foundation model that jointly models histologic, genomic, epigenetic and transcriptomic modalities, producing an integrated patient representation that reflects tumor biology more comprehensively. Our approach incorporates three key components: (1) multimodal SigLIP loss enabling all-pairwise contrastive learning across heterogeneous modalities, (2) a fragment-aware rotary positional encoding (F-RoPE) module that preserves spatial structure and tissue-fragment topology in WSI, and (3) domain-specialized internal foundation models for both WSI and RNA-seq to provide biologically grounded embeddings for robust multimodal alignment. We evaluate EXAONE Path 2.5 against six leading pathology foundation models across two complementary benchmarks: an internal real-world clinical dataset and the Patho-Bench benchmark covering 80 tasks. Our framework demonstrates high data and parameter efficiency, achieving on-par performance with state-of-the-art foundation models on Patho-Bench while exhibiting the highest adaptability in the internal clinical setting. These results highlight the value of biologically informed multimodal design and underscore the potential of integrated genotype-to-phenotype modeling for next-generation precision oncology.

